PRESCRIBING INFORMATION (UK) Campral EC acamprosate Presentation: Off-white round enteric-coated tablets, containing 333mg acamprosate calcium. Indications: Maintenance of abstinence in alcohol-dependent patients. It should be combined with counselling. Dosage and Administration: Adults ≥ 60kg: 6 tablets per day (2 tablets taken three times daily with meals) Adults < 60kg: 4 tablets per day (2 tablets in the morning, 1 at noon and 1 at night with meals). Recommended treatment period is one year, starting as soon as possible after the withdrawal period. Treatment should be maintained if the patient relapses. Elderly and children: Not recommended. Contraindications: Known hypersensitivity to the drug; renal insufficiency (serum creatinine > 120 micromol/L); lactating women. Warnings and precautions: Does not prevent the harmful effects of continuous alcohol abuse; continued alcohol abuse negates the therapeutic benefit; regular monitoring of mental status for symptoms of depression or suicidality is recommended. The safety and efficacy of Campral have not been established in patients with severe liver insufficiency (Childs-Pugh Classification C). Safety and efficacy are also not established in those under 18 or over 65 years old. Interactions: None observed in pharmacokinetic studies with diazepam, disulfiram, oxazepam, tetrabamate, meprobamate or imipramine. In clinical trials, Campral has been safely administered with antidepressants, anxiolytics, hypnotics, sedatives and non-opioid analgesics. The concomitant intake of alcohol and Campral does not affect the pharmacokinetics of either alcohol or Campral; administration with food diminishes the bioavailability of Campral compared with administration in a fasting state. There is no information on administration of Campral with diuretics. Pregnancy: Campral should only be used during pregnancy after a careful benefit/risk assessment, when the patient cannot abstain from drinking alcohol without being treated with Campral, and when there is a consequential risk of foetotoxicity or teratogenicity due to alcohol. Undesirable Effects: Very common: diarrhoea; Common: abdominal pain, nausea, vomiting, flatulence, pruritus, maculo-papular rash, frigidity or impotence, decreased libido; Uncommon: increased libido; Very rare: hypersensitivity reactions including urticaria, angio-oedema or anaphylactic reactions; Unknown frequency: vesiculo-bullous eruptions. Prescribers should consult the summary of product characteristics for full details of side effects. Overdose: In reported cases, the related symptom is diarrhoea. Treatment of overdose is directed to symptoms. Legal Category: POM Package Quantities and Basic NHS Price: 168 blister packed tablets Price £28.80 Marketing Authorisation Number/Holder: PL 13466/0001, Merck Santé s.a.s, 37 rue Saint Romain, 69379 Lyon Cedex 08, France Further information is available from: Merck Serono Ltd, Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX, UK. Date of preparation: February 2012
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Merck Serono Limited - Tel: +44(0)20 8818 7373 or email: [email protected].
HALFLYTELY BOWEL PREP INSTRUCTIONS Procedure Date/Time___________________ Registration Time____________ St. Joseph East Office Park Ky Surgery Center GI Care Center BGCH Dr. Laurie Haas Dr. Kathleen Martin Dr. Daniell Hill PLEASE READ CAREFULLY THIS ENTIRE SHEET BEFORE YOU BEGIN PREP DAY (The day before the procedure)Do NOT eat any solid food this day. CLEAR LIQUIDS ONLY. A clea
HASTA (HyperAkut STroke Alarm) Formulär Ambulans Uppgiftslämnare: Cert nr: _____________Namn: _____________________________________ Patientens namn: ______________________________________________________________ Är patienten randomiserad av SOS Alarm vid utlarmning? Ja, till HASTA Prio 1 HASTA Standard Om icke randomiserad patient med stroke-symtom uppfyller kriterier för